An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
2022 · BMC Health Services Research · 2 citations
https://doi.org/10.1186/s12913-022-08274-x